A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between tho...

Descripción completa

Detalles Bibliográficos
Autores principales: Bratherton, D. G., Brown, C. H., Buchanan, R., Hall, V., Kingsley Pillers, E. M., Wheeler, T. K., Williams, C. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1984
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976875/
https://www.ncbi.nlm.nih.gov/pubmed/6380554
_version_ 1782135144405008384
author Bratherton, D. G.
Brown, C. H.
Buchanan, R.
Hall, V.
Kingsley Pillers, E. M.
Wheeler, T. K.
Williams, C. J.
author_facet Bratherton, D. G.
Brown, C. H.
Buchanan, R.
Hall, V.
Kingsley Pillers, E. M.
Wheeler, T. K.
Williams, C. J.
author_sort Bratherton, D. G.
collection PubMed
description In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between those randomised to 10 mg and those to 20 mg twice daily. Although the mean serum concentration of tamoxifen in the 20 mg bd group was significantly higher no correlation between serum level and clinical benefit was demonstrated.
format Text
id pubmed-1976875
institution National Center for Biotechnology Information
language English
publishDate 1984
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19768752009-09-10 A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Bratherton, D. G. Brown, C. H. Buchanan, R. Hall, V. Kingsley Pillers, E. M. Wheeler, T. K. Williams, C. J. Br J Cancer Research Article In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between those randomised to 10 mg and those to 20 mg twice daily. Although the mean serum concentration of tamoxifen in the 20 mg bd group was significantly higher no correlation between serum level and clinical benefit was demonstrated. Nature Publishing Group 1984-08 /pmc/articles/PMC1976875/ /pubmed/6380554 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Bratherton, D. G.
Brown, C. H.
Buchanan, R.
Hall, V.
Kingsley Pillers, E. M.
Wheeler, T. K.
Williams, C. J.
A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
title A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
title_full A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
title_fullStr A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
title_full_unstemmed A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
title_short A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
title_sort comparison of two doses of tamoxifen (nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976875/
https://www.ncbi.nlm.nih.gov/pubmed/6380554
work_keys_str_mv AT brathertondg acomparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT brownch acomparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT buchananr acomparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT hallv acomparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT kingsleypillersem acomparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT wheelertk acomparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT williamscj acomparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT brathertondg comparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT brownch comparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT buchananr comparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT hallv comparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT kingsleypillersem comparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT wheelertk comparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd
AT williamscj comparisonoftwodosesoftamoxifennolvadexinpostmenopausalwomenwithadvancedbreastcancer10mgbdversus20mgbd

Ejemplares similares